Covariance-Insured Screening.

Modern bio-technologies have produced a vast amount of high-throughput data with the number of predictors far greater than the sample size. In order to identify more novel biomarkers and understand biological mechanisms, it is vital to detect signals weakly associated with outcomes among ultrahigh-dimensional predictors. However, existing screening methods, which typically ignore correlation information, are likely to miss weak signals. By incorporating the inter-feature dependence, a covariance-insured screening approach is proposed to identify predictors that are jointly informative but marginally weakly associated with outcomes. The validity of the method is examined via extensive simulations and a real data study for selecting potential genetic factors related to the onset of multiple myeloma.